@entity18151 , consisting of @entity2879 , @entity2664 , and @entity2592 , is a timed-sequential chemotherapy (TSC) regimen and an efficacious option for induction treatment of @entity3052 ( @entity3052 ). Hematopoietic growth factors (HGFs) have been shown to recruit leukemic blasts into cell cycle. We postulated the addition of @entity1261 ( @entity1261 ) to @entity18151 ( @entity18151 ) might enhance treatment efficacy. @entity18151 consisted of mitoxantrone on days 1-3, @entity2592 on days 1-3 and 8-10, etoposide on days 8-10, and @entity1261 from day 4 until absolute neutrophil count (ANC) >500/microl. In total, 28 @entity1 were enrolled. All @entity1 had newly diagnosed de novo @entity3052 . The median age was 42 years. Of the 27 @entity1 with cytogenetic analysis, six had favorable karyotype, 18 intermediate karyotype, and three unfavorable karyotype. The median follow-up was 37.5 months. The median time for both ANC recovery and last platelet transfusion was 26 days. The @entity137 associated with this regimen were no more than those expected with the standard chemotherapy. In all, 24 (86%) @entity1 achieved complete remission (CR), three (11%) @entity1 had no response, and one @entity1 died within 24 h of induction therapy before response could be evaluated. Of the 24 @entity1 who achieved CR, 22 received high-dose @entity2592 and two received allogeneic bone marrow transplant as initial postremission therapy. For the whole cohort, the estimated 3-year survival rate was 67%. The median relapse-free survival was 30.5 months. We conclude that @entity18151 regimen is a safe regimen and administration of @entity1261 during and after induction treatment is not associated with prolongation of marrow @entity3894 or acceleration of @entity1778 relapse. It is efficacious for induction therapy for newly diagnosed de novo @entity3052 . A high CR rate can be achieved with only one course of this chemotherapy.

Timed-sequential chemotherapy with concomitant XXXX for newly diagnosed de novo @entity3052 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity1261 :: ('1440', 'Gene') :: ['G-CSF', 'granulocyte colony-stimulating factor'] @entity2664 :: ('MESH:D008942', 'Chemical') :: ['mitoxantrone'] @entity18151 :: ('MESH:C538387', 'Disease') :: ['EMA', 'EMA-G'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myelogenous leukemia', 'AML'] @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytosine arabinoside', 'cytarabine'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukemia'] @entity3894 :: ('MESH:C563261', 'Disease') :: ['aplasia']
@entity1261 :: (1440,Gene) :: ['granulocyte colony-stimulating factor']
